Breast Cancer


Recent studies have established a role for these new, targeted drugs that are effective in treating certain sub-types of breast cancer :


TDM1 (also known as Kadcyla ®) is approved for use by both the FDA and the EU as a single agent treatment  for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer who previously received Herceptin (trastuzumab) and a taxane, separately or in combination.


Pertuzumab (also known as Perjeta ®) is a type of personalised medicine approved by the FDA and EU, given in combination with Herceptin (trastuzumab) for the treatment of patients with previously untreated HER2-positive metastatic breast cancer. Perjeta is designed to prevent the HER2 receptor from pairing with other HER receptors on the surface of cells, a mechanism that is complementary to Herceptin. Used together, the combination is thought to provide a more comprehensive blockade of HER signalling pathways.


Oncotype DX ®    Another exciting development in the management of breast cancer is a new tool that helps clinicians clarify a patient’s specific treatment plan. The Oncotype DX ® test analyses the activity of 21 genes within a patient’s tumour, to provide an individual Recurrence Score ® result, unique to the biology of a patient’s cancer. The test may be used when the benefits of specific chemotherapy drugs may be uncertain in an individual patient – it can help enhance both the patient’s and the doctor’s confidence in treatment decisions.

Blog Categories

Blog Archive

Finding Us